Researchers have developed a technique that could allow astronauts to grow fresh medicines in space using genetically modified plants. The approach aims to address the challenge of pharmaceutical supply on long-duration missions, where resupply from Earth is impractical and shelf-life limits the use of pre-manufactured drugs.
The method involves using plants as bioreactors to produce therapeutic proteins and peptides. By activating specific genetic sequences, plants can synthesize complex pharmaceutical compounds on demand. This could enable crews to manufacture treatments for conditions such as radiation exposure, bone loss, or infection during missions to Mars or beyond.
While the research is still at an early proof-of-concept stage, the team demonstrated that tobacco plants, which grow quickly and are well understood, can produce a model protein within a few weeks under controlled conditions. The system is designed to be compact and energy-efficient, critical constraints for spacecraft habitats.
Beyond space exploration, the technology could have profound benefits on Earth. In regions with limited access to pharmaceutical manufacturing or cold-chain storage, locally grown plants could produce essential medicines at low cost, reducing dependency on centralized production and distribution networks.
The work underscores a broader push toward in-situ resource utilization and biomanufacturing for space travel. However, scaling the method for diverse drug molecules and ensuring regulatory approval for space use remain significant hurdles.